Targets › NICOTINAMIDE
1 program from 1 company in 1 trial: 1 Phase 3; Neurology.
Open in Phaseline: the race on NICOTINAMIDE, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| ScandiBio Therapeutics | CMA2 Combined metabolic activator containing N-acetyl-L-cysteine, L-carnitine-L-tartrate, nicot | NAC, LCAT, NICOTINAMIDE, L-SERINE | Phase 3 | Alzheimer Disease | – |
Alzheimer Disease (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.